{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-017323","form_type":"8-K/A","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.698889+00:00","generated_at":"2026-05-16T02:33:39.941877+00:00","sec_items":["9.01","2.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M","bullets":["Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.","No revenue from operations; digital assets at fair value $132.3M (incl. restricted).","Total equity $132.3M, zero liabilities; unrealized loss $9.1M from digital asset remeasurement.","Financials filed as Exhibit 99.1 for reverse merger with Apimeds (APUS) previously reported.","Company holds crypto tokens ($NILA) and generates gains mainly from sale of digital assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-017323","json":"https://secwatch.observer/filing/0001213900-26-017323.json","markdown":"https://secwatch.observer/filing/0001213900-26-017323.md","text":"https://secwatch.observer/filing/0001213900-26-017323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026017323/0001213900-26-017323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026017323/ea0277267-8ka2_api.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:33:39.941877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}